• -11%
  • New
T3 - Liothyronine | Dragon Pharma
search
  • T3 - Liothyronine | Dragon Pharma

T3

$42.00
$37.38 Save 11%

Liothyronine Sodium

T3 / Cytomelβ€’25 mcg/tab
Class Active Thyroid Hormone
Half-Life ~2.5 days
Receptor Thyroid Hormone Receptor (TRΞ±/TRΞ²)
Suppression TSH / T4 (Thyroid Axis)
Pack 100 tabs
Form Oral Tablet

Quantity

  Security policy

(edit with the Customer Reassurance module)

  Delivery policy

(edit with the Customer Reassurance module)

  Return policy

(edit with the Customer Reassurance module)

Liothyronine Sodium (T3) 25mcg by Dragon Pharma

T3 is Dragon Pharma's formulation of Liothyronine Sodium β€” synthetic triiodothyronine β€” at 25mcg per tablet. T3 is the active form of thyroid hormone that directly binds thyroid hormone receptors in cells throughout the body, regulating basal metabolic rate at the gene expression level. It is the most powerful BMR-elevating compound in the Dragon Pharma range β€” more potent than both Clenbuterol and Salbutamol at the metabolic level, and the only one that acts through thyroid receptor gene regulation rather than adrenergic receptor signalling.

Also searched as: T3 25mcg, Liothyronine Sodium, Cytomel, Tiromel, T3 fat loss Dragon Pharma.

T3 vs T4 β€” The Active Form Distinction

The thyroid gland produces two hormones: T4 (thyroxine, levothyroxine) and T3 (triiodothyronine, liothyronine). Their relationship is frequently misunderstood:

  • T4 (Levothyroxine) is the primary secretory product of the thyroid gland β€” approximately 80-90% of thyroid output is T4. However, T4 is largely a prohormone β€” it has weak direct thyroid receptor activity itself
  • T3 (Liothyronine) is the biologically active form β€” it binds thyroid hormone receptors (TRΞ± and TRΞ²) with approximately 3-4Γ— greater affinity than T4. Most T4 is converted to T3 in peripheral tissues (primarily liver and kidney) by deiodinase enzymes that remove one iodine atom
  • Exogenous T3 bypasses the T4β†’T3 conversion step entirely β€” it delivers the active hormone directly to thyroid receptors without relying on peripheral deiodinase activity
  • This is why T3 produces a more immediate and potent metabolic effect than equivalent doses of T4 β€” there is no conversion step limiting its bioavailability at the receptor
  • T3's ~2.5 day half-life also allows faster dose titration than T4's ~7-day half-life β€” making T3 more practical for the short cycling windows used in performance contexts

How T3 Elevates Basal Metabolic Rate β€” The Mechanism

T3 is the most potent metabolic accelerator in the Dragon Pharma range. Unlike Clenbuterol and Salbutamol which act on adrenergic receptors, T3 acts directly at the genetic level:

  • T3 enters cells and binds thyroid hormone receptors (TRΞ± and TRΞ²) in the cell nucleus β€” nuclear receptors that directly regulate gene transcription
  • T3-receptor complexes bind thyroid response elements (TREs) in the promoter regions of hundreds of metabolic genes β€” directly upregulating or downregulating their expression
  • Key genes activated: Na⁺/K⁺-ATPase (increases futile ion cycling, generating heat); uncoupling proteins (increase mitochondrial heat production); enzymes of fatty acid oxidation, glucose metabolism and amino acid catabolism
  • The result is a global acceleration of cellular metabolic activity β€” increased oxygen consumption, increased heat generation and increased nutrient turnover across all tissues simultaneously
  • This mechanism is systemic and non-selective β€” unlike Clenbuterol which primarily targets adipose tissue and skeletal muscle via beta-2 receptors, T3 accelerates metabolism in every cell type with thyroid receptors β€” which is essentially all cells

T3 vs Clenbuterol vs Salbutamol β€” The Three-Way Metabolic Comparison

Parameter T3 (Liothyronine) Clenbuterol Salbutamol
Receptor target Thyroid hormone receptors TRΞ±/TRΞ² (nuclear) Beta-2 adrenergic receptor Beta-2 adrenergic receptor
Mechanism Gene transcription regulation β€” systemic cAMP signalling β€” thermogenic cAMP signalling β€” thermogenic
BMR elevation Most potent β€” systemic metabolic acceleration Moderate β€” 5-10% above baseline Mild β€” less potent than Clenbuterol
Muscle catabolism risk High β€” accelerates all energy substrate catabolism Low β€” anti-catabolic via mTOR Low β€” anti-catabolic via mTOR
Receptor downregulation Does not downregulate β€” sustained efficacy ~50% in 2 weeks β€” cycling required Partial β€” slower than Clenbuterol
Axis suppression Yes β€” suppresses TSH and T4 production None None
Discontinuation Must taper β€” abrupt stop risks rebound hypothyroidism Can stop abruptly Can stop abruptly

Why T3 Must Be Tapered β€” The Thyroid Axis Recovery

This is the most clinically important aspect of T3 use and the least adequately explained in competitor content:

  • Exogenous T3 suppresses the HPT (hypothalamic-pituitary-thyroid) axis through negative feedback β€” elevated T3 signals the hypothalamus and pituitary to reduce TRH (thyrotropin-releasing hormone) and TSH (thyroid-stimulating hormone) output
  • Without TSH signalling, the thyroid gland reduces T3 and T4 production β€” the gland partially atrophies during prolonged suppression
  • When exogenous T3 is stopped abruptly, there is a window where: exogenous T3 has cleared, natural TSH production has not yet recovered, and the thyroid gland has not yet resumed full output. This creates a transient hypothyroid state β€” low metabolism, fatigue, cold sensitivity and potential fat rebound
  • Gradual tapering allows TSH to recover progressively as exogenous T3 doses decline β€” the thyroid axis restores function in step with the reducing exogenous load rather than facing an abrupt withdrawal
  • The standard taper: reduce dose by 12.5-25mcg every 1-2 weeks until reaching the lowest dose before stopping

Effects and Benefits

  • Significant BMR elevation β€” the most potent non-stimulant metabolic accelerator available
  • Accelerated fat loss when combined with caloric deficit β€” systemic nutrient turnover acceleration
  • No receptor downregulation β€” efficacy maintained throughout the cycle (unlike beta-2 agonists)
  • Conversion of T4-based metabolism to active T3 signalling without reliance on peripheral conversion

Dosage and Administration

Phase Dose Duration Notes
Initiation 25 mcg/day (1 tab) 1–2 weeks Assess tolerance; single tab is starting dose
Maintenance 50–75 mcg/day 4–6 weeks Most commonly used range
Advanced 75–125 mcg/day 4 weeks maximum High catabolic risk; AAS base essential
Taper Reduce by 25 mcg every 1–2 weeks 2–4 weeks Never stop abruptly

At 25mcg per tablet, dosing is straightforward β€” the 25mcg tablet is both the starting dose and the standard taper increment. Twice-daily dosing at the maintenance phase (e.g. 25mcg morning + 25mcg midday) distributes the dose across T3's ~2.5-day half-life more evenly, though once-daily dosing is also commonly used. T3's catabolic potential at doses above 50mcg/day makes an AAS testosterone base strongly advisable to protect lean mass.

Comments (0)
No customer reviews for the moment.